Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624078 · ClinicalTrials.gov registry record · Phase 2
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
A Phase 2 study, sponsored by Instituto Bioclon S.A. de C.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 1,426
- Enrollment target
NCT00624078 is a Phase 2 study that has completed, run by Instituto Bioclon S.A. de C.V.. The registered enrollment target is 1,426 participants.
The verdict
NCT00624078, a Phase 2 study, has completed, sponsored by Instituto Bioclon S.A. de C.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,426 participants
- Enrollment target
Study Summary
This treatment protocol will enable therapeutic use of Anascorp in the management of systemic manifestations of scorpion sting envenomation, in patients for whom antivenom would otherwise be unavailable. The working hypotheses are as follows: 1. The investigational antivenom is safe as treatment of scorpion sting envenomation. 2. The investigational antivenom is effective as treatment of scorpion sting envenomation.
Interventions
- DRUG Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,426 participants |
| Start Date | 2005-05 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624078
The ClinicalTrials.gov registry entry for NCT00624078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Instituto Bioclon S.A. de C.V., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antivenin Centruroides (scorpion) F(ab)2 Anascorp™ is the first listed.
NCT00624078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00624078 about?
NCT00624078 is a clinical study titled "Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation". This treatment protocol will enable therapeutic use of Anascorp in the management of systemic manifestations of scorpion sting envenomation, in patients for whom antivenom would otherwise be unavailable. The working hypotheses are as follows: 1. The investigational antivenom is safe as treatment of...
What is the current status of trial NCT00624078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,426 participants. The study started on 2005-05. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00624078?
The interventions under investigation include: Antivenin Centruroides (scorpion) F(ab)2 Anascorp™ (DRUG).
Who is sponsoring clinical trial NCT00624078?
This trial is sponsored by Instituto Bioclon S.A. de C.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.